Takfa Oint 0.03%

TAKFA OINT 0.03%

TAKFA OINT 0.03% is a topical medication manufactured by INTAS PHARMACEUTICALS LTD, primarily used for the treatment of certain skin conditions.

Composition

TAKFA OINT 0.03% contains Tacrolimus 0.03% w/w as its active ingredient. Tacrolimus is an immunosuppressant belonging to the class of calcineurin inhibitors. It works by suppressing the immune response in the skin, thereby reducing inflammation, itching, and redness associated with eczema.

Uses

TAKFA OINT 0.03% is primarily used for the treatment of moderate to severe atopic dermatitis (eczema) in adults and children over 2 years of age who have not responded well to other treatments, such as topical corticosteroids. Atopic dermatitis is a chronic skin condition characterized by itchy, dry, flaky, swollen, rough, and irritated skin. This ointment helps to alleviate inflammation, itching, and redness. While other formulations of Tacrolimus are used to prevent organ rejection, TAKFA OINT 0.03% is specifically for topical skin conditions.

Dosage and Administration

TAKFA OINT 0.03% is for external use only. It should be applied as a thin layer to the affected skin areas, typically twice daily, or as directed by a healthcare professional. The ointment should be gently rubbed into the skin until it is evenly distributed.

• Clean and dry the infected area well before application.
• Wash hands thoroughly before and after applying the ointment, unless the hands are the area being treated.
• Avoid covering the treated area with bandages, wraps, or other wound dressings unless advised by a doctor.
• Avoid contact with eyes, nose, mouth, or any open wounds. If accidental contact occurs, rinse thoroughly with clean water.
• For children aged 2 to 15 years, apply a thin layer to affected areas twice daily and continue for 1 week after symptoms resolve. The 0.03% strength is not recommended for children below two years of age.

Side Effects

Common side effects of TAKFA OINT 0.03% include application site reactions such as:

• Burning or tingling sensation, pain, itching, irritation.
• Redness, dryness, peeling, or rash at the application site.
• Increased skin sensitivity, especially to sunlight.
• Headache.

More serious, though rare, side effects can include an increased risk of inflamed or infected hair follicles, cold sores, acne, and generalized herpes simplex infections. Long-term use has been associated with an increased risk of lymph node tumors (lymphoma) and skin cancer, though a causal relationship has not been definitively established. Consult a doctor if side effects persist or worsen.

Precautions

• Allergies: Do not use if allergic to Tacrolimus or any other ingredients in TAKFA OINT.
• Sunlight Exposure: Avoid or minimize exposure to natural and artificial sunlight while using this medicine, and use protective clothing and high SPF sunscreen due to increased skin sensitivity.
• Broken or Infected Skin: Do not apply to broken, infected, or oozing skin.
• Pregnancy and Breastfeeding: Limited information is available regarding safety during human pregnancy. It is not recommended during breastfeeding as Tacrolimus passes into breast milk. Consult a doctor if pregnant, planning a pregnancy, or breastfeeding.
• Children: The 0.03% strength is not recommended for use in children below two years of age.
• Other Conditions: Discuss with your doctor if you have liver diseases, skin tumors, a weak immune system, or rare genetic skin diseases like Netherton's syndrome or lamellar ichthyosis.
• Drug Interactions: While topical application has minimal systemic absorption, discuss with your doctor if you are using other topical medicines as interactions may occur. Caution is advised with certain oral medications like erythromycin, itraconazole, ketoconazole, and diltiazem. Avoid consuming alcohol as it may cause skin redness.
• Moisturizers: It is generally recommended to wait at least 30 minutes after applying TAKFA OINT 0.03% before applying other skincare products.

Storage

TAKFA OINT 0.03% should be stored at room temperature, in its original container, in a clean and dry place, away from heat, moisture, and direct sunlight. Keep the medicine out of reach of children and pets. Store below 30°C. Do not use expired or damaged medicines.

TAKFA OINT 0.03% is a topical medication containing tacrolimus, primarily used for the treatment of moderate to severe atopic dermatitis (eczema). It is manufactured by Intas Pharmaceuticals Ltd.

What is TAKFA OINT 0.03% used for?

TAKFA OINT 0.03% is prescribed for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis, also known as eczema, in adults and children aged 2 years and older. It is typically used when other topical treatments, such as corticosteroids, have not been effective or are not advisable.

How does TAKFA OINT 0.03% work?

The active ingredient, tacrolimus, is a topical calcineurin inhibitor. It works by suppressing the skin's immune response, which helps to reduce the allergic reaction, inflammation, itching, and redness associated with eczema. Tacrolimus achieves this by inhibiting T-cell activation and the production of certain inflammatory chemicals in the skin.

What is the usual dosage for TAKFA OINT 0.03%?

A thin layer of TAKFA OINT 0.03% should be applied to the affected skin areas twice daily, or as directed by your doctor. It is crucial to use the smallest amount needed to cover the affected area and rub it in gently and completely. For children aged 2 to 15 years, only the 0.03% strength is recommended. Treatment should be stopped when symptoms clear, and continuous long-term use should be avoided. If symptoms do not improve after 6 weeks, or if they worsen, consult your doctor.

What are the possible side effects of TAKFA OINT 0.03%?

Common side effects at the application site include burning, stinging, soreness, itching, redness, or irritation. These are usually mild to moderate and tend to diminish within the first few days of treatment as the skin heals. Other possible side effects include headache, acne, small red bumps on the skin (folliculitis), stomach upset, flu-like symptoms, or increased sensitivity of the skin to hot/cold/pain/touch. Rare but serious side effects reported with topical calcineurin inhibitors include unusual skin changes, changes in moles, unusual growths, or swollen lymph nodes. Although a causal relationship has not been definitively established, there is a potential risk of skin cancer or lymphoma with long-term use, so continuous long-term application should be avoided.

Is TAKFA OINT 0.03% safe during pregnancy or breastfeeding?

During Pregnancy: This medication should be used during pregnancy only when clearly needed, and you should discuss the potential risks and benefits with your doctor. Topical absorption of tacrolimus is very low, and studies on oral tacrolimus have not shown an increased risk of congenital malformations, though an increased risk of prematurity has been noted, possibly related to maternal disease. During Breastfeeding: It is not known if tacrolimus passes into breast milk after topical application. However, topical tacrolimus presents a low risk to a nursing infant due to poor absorption through the skin. If used on the breast area, ensure the infant's skin does not come into direct contact with the treated areas, and gently clean the nipples before feeding.

Can TAKFA OINT 0.03% be taken with other medications?

TAKFA OINT 0.03% is applied externally, making systemic interactions with oral medications less likely. However, it may interact with other topical creams, lotions, or gels. Inform your doctor about all medications, vitamins, and herbal products you are using. Specific medications that may interact include cimetidine, erythromycin, itraconazole, ketoconazole, fluconazole, diltiazem, nifedipine, nimodipine, nisoldipine, and vaccines. Do not apply moisturizers within 2 hours of applying TAKFA OINT 0.03%.

What precautions should be taken while using TAKFA OINT 0.03%?

Avoid continuous long-term use and limit application to areas affected by eczema. Protect your skin from excessive sun exposure, including tanning booths and sunlamps, by using sunscreen and wearing protective clothing. Do not apply the ointment to open wounds, infected areas, or skin with cancers or pre-cancers. Avoid getting the ointment in your eyes, nose, or mouth; if contact occurs, rinse thoroughly with water. Do not cover the treated area with bandages, dressings, or wraps unless specifically instructed by your doctor. Limit alcohol intake as it may cause skin flushing. This ointment is not recommended for children younger than 2 years of age. Inform your doctor about your medical history, especially if you have immune system problems, cancer (especially skin cancer), kidney disease, or conditions like Netherton's syndrome.

What happens if a dose of TAKFA OINT 0.03% is missed?

If you miss a dose, apply it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not apply a double dose to make up for a missed one.

How should TAKFA OINT 0.03% be stored?

Store TAKFA OINT 0.03% at room temperature, ideally between 20°C and 25°C (68°F and 77°F). Keep it in its original container with the lid tightly closed, in a dry place, and away from excess heat and moisture (do not store in the bathroom). Keep all medications, including TAKFA OINT 0.03%, out of reach of children and pets.